Practical Management of Thyroid Cancer
138,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 1-2 Wochen
payback
69 °P sammeln
  • Gebundenes Buch

Written by leading world experts, this third edition embraces the philosophy of international collaboration and disseminates the latest advances and transformative changes in the field of thyroid cancer. It provides a global health perspective, striving towards a uniform, equitable, evidence-based, cost-effective, practical, and patient-centred approach with high quality care crossing geographical boundaries. This book covers controversial issues and the most up-to-date management of differentiated, medullary, anaplastic, and rarer types of thyroid cancers together with survivorship issues and…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
Written by leading world experts, this third edition embraces the philosophy of international collaboration and disseminates the latest advances and transformative changes in the field of thyroid cancer.
It provides a global health perspective, striving towards a uniform, equitable, evidence-based, cost-effective, practical, and patient-centred approach with high quality care crossing geographical boundaries. This book covers controversial issues and the most up-to-date management of differentiated, medullary, anaplastic, and rarer types of thyroid cancers together with survivorship issues and the lessons learnt during the Covid-19 Pandemic.

The molecular landscape of thyroid cancers has a high frequency of oncogenic driver mutations and a high frequency of gene fusions treatable by new gene-specific systemic therapies. These include dual MAPK (Dabrafenib) / MEK (Trametinib) inhibition in BRAF V 600E mutated Anaplastic Thyroid Cancer, Larotrectinib, Entrectinib for NTRKgene fusion, Selpercartinib, Pralsetinib for RET fusion and mutations. These, newer and Master protocol trials, Tumour Agnostic drug development, Immune Checkpoint blockade and CAR-T therapy etc are discussed.

The latest NICE and African Guidelines for Management are included. This would be of interest to readers as well.

This book is aimed at thyroidologists of all disciplines, (in training or experts) students, non-specialist clinicians, nursing staff, all the disciplines involved in a multidisciplinary team such as surgeons - Head & Neck or Endocrine and General Surgeons, Oncologists, Endocrinologists, Nuclear Medicine Physicians, Nuclear Medicine Physicists, Radiologists, Pathologists, Specialist Nurses, Geneticists, Clinical Psychologists, Palliative Care Physicians and, in addition to AI in medicine, telemedicine experts, health policy makers, and scientists.

Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Autorenporträt
Dr Ujjal Mallick, MBBS MS FRCPE (Hon) FRCP (Hon) FRCR Consultant Clinical Oncologist Formerly Consultant Oncologist and  past Chair, Multidisciplinary thyroid cancer team (MDT), Freeman Hospital, Newcastle upon Tyne, UK, a centre of excellence for thyroid cancer. Chief Investigator of the first UK National Thyroid Cancer Trial -Hilo-( NEJM 2012) which helped modify international guidelines and practice and of the on-going second UK trial-IoN. One of the lead authors of the first UK National guideline. The MDT obtained many prestigious national awards including-Best NHS "Hospital Doctor" Oncology Team of the Year" Award 2007, Best Thyroid cancer MDT in NHS Peer Review 2011, first prize in NHS innovations award 2007 and others. He initiated an acclaimed MD clinic involving an expert thyroid cancer patient. Current interests are trials, biomarkers and guideline implementation.  Dr Clive Harmer MB FRCR FRCP. Clinical Oncologist Consultant in Clinical Oncology at St. George's Healthcare NHS Trust and The Royal Marsden NHS Trust (where he was head of the Thyroid unit) until August 2005. Recognized teacher of the University of London and Honorary Senior Lecturer at the Institute of Cancer Research.